COSCIENS Biopharma Inc. (NASDAQ:CSCI) — Market Cap & Net Worth
Market Cap & Net Worth: COSCIENS Biopharma Inc. (CSCI)
COSCIENS Biopharma Inc. (NASDAQ:CSCI) has a market capitalization of $8.64 Million ($8.64 Million) as of October 13, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27494 globally and #5708 in its home market, demonstrating a 4.79% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying COSCIENS Biopharma Inc.'s stock price $7.65 by its total outstanding shares 3177040 (3.18 Million).
COSCIENS Biopharma Inc. Market Cap History: 2015 to 2026
COSCIENS Biopharma Inc.'s market capitalization history from 2015 to 2026. Data shows change from $1.42 Billion to $24.30 Million (-32.97% CAGR). Check CSCI stock price for real-time trading data and today's change.
Index Memberships
COSCIENS Biopharma Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #784 of 976 |
Weight: COSCIENS Biopharma Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
COSCIENS Biopharma Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how COSCIENS Biopharma Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see COSCIENS Biopharma Inc. cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.64x
COSCIENS Biopharma Inc.'s market cap is 0.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.42 Billion | $7.69 Million | $3.55 Million | 185.15x | 401.27x |
| 2016 | $1.14 Billion | $10.17 Million | $2.69 Million | 112.42x | 424.68x |
| 2017 | $749.78 Million | $10.28 Million | -$762.05K | 72.94x | N/A |
| 2018 | $934.05 Million | $8.51 Million | -$231.67K | 109.74x | N/A |
| 2019 | $289.11 Million | $9.86 Million | -$867.07K | 29.32x | N/A |
| 2020 | $136.61 Million | $11.86 Million | $1.46 Million | 11.52x | 93.85x |
| 2021 | $114.37 Million | $13.49 Million | $2.64 Million | 8.48x | 43.33x |
| 2022 | $40.41 Million | $14.57 Million | $3.45 Million | 2.77x | 11.72x |
| 2023 | $23.64 Million | $7.14 Million | -$3.48 Million | 3.31x | N/A |
| 2024 | $8.80 Million | $13.78 Million | -$15.31 Million | 0.64x | N/A |
Competitor Companies of CSCI by Market Capitalization
Companies near COSCIENS Biopharma Inc. in the global market cap rankings as of October 13, 2026. See debt-free asset ratio of COSCIENS Biopharma Inc. to understand what proportion of total assets are financed by equity.
Key companies related to COSCIENS Biopharma Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
COSCIENS Biopharma Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, COSCIENS Biopharma Inc.'s market cap moved from $1.42 Billion to $ 24.30 Million, with a yearly change of -32.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $24.30 Million | +267.79% |
| 2025 | $6.61 Million | -24.91% |
| 2024 | $8.80 Million | -62.77% |
| 2023 | $23.64 Million | -41.51% |
| 2022 | $40.41 Million | -64.67% |
| 2021 | $114.37 Million | -16.28% |
| 2020 | $136.61 Million | -52.75% |
| 2019 | $289.11 Million | -69.05% |
| 2018 | $934.05 Million | +24.58% |
| 2017 | $749.78 Million | -34.44% |
| 2016 | $1.14 Billion | -19.64% |
| 2015 | $1.42 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 12th, 2026 the market cap of COSCIENS Biopharma Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.64 Million USD |
| MoneyControl | $8.64 Million USD |
| MarketWatch | $8.64 Million USD |
| marketcap.company | $8.64 Million USD |
| Reuters | $8.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reducti… Read more